Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery.
Terlizzi M, Buscail E, Boussari O, Adgié S, Leduc N, Terrebonne E, Smith D, Blanc JF, Lapuyade B, Laurent C, Chiche L, Belleannée G, Le Malicot K, Trouette R, Pouypoudat C, Vendrely V.
Terlizzi M, et al. Among authors: boussari o.
Acta Oncol. 2021 Sep;60(9):1114-1121. doi: 10.1080/0284186X.2021.1944662. Epub 2021 Jul 1.
Acta Oncol. 2021.
PMID: 34197269